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Metastatic renal cell carcinoma has a poor prognosis. One-third of
the patients with renal cell carcinoma present with metastatic
disease and one-half of the other patients will develop metastases
during further follow-up. The median survival is only 6 months
and the 5-year-survival is less than 5% (Linehan et al, 1997).
Conventional systemic therapies such as chemotherapy and
hormonal therapy generally induce response rates below 10% and
have no impact on survival (Fossa et al, 1994; Kjaer, 1988). In
view of the wide variability in the natural history of the disease
with, on the one hand, sometimes rapid progression and, on the
other hand, the occurrence of spontaneous regression of metas-
tases, it is thought that immune mechanisms may play a role.
Therefore, biologic response modifiers have undergone extensive
evaluation. Interferon-a (IFN-a) and interleukin-2 (IL-2), both as
single-agent and in various combinations, are the best investigated
agents. IFN-a results in response rates of 8–26%, with a median
survival of 13 months (Negrier et al, 1998; Creagan et al, 1991;
Umeda and Niijima, 1986). IL-2 induces a response rate of
7–23%, with a median survival of 12 months (Negrier et al, 1998;
Fyfe et al, 1996; Gore et al, 1994). The combination of the two
cytokines has only given a slight increase in response rate (Negrier
et al, 1998; Palmer et al, 1993; Atzpodien et al, 1995; Facendola et
al, 1995). In randomized studies comparing the combination of
IFN-a and IL-2 with each single agent no survival advantage was
found (Negrier et al, 1998; Jayson et al, 1998).
To improve these results, several groups have investigated the
combination of these cytokines with chemotherapy. In 1993,
Atzpodien et al reported a 48% response rate (95% confidence
interval (CI) 32–66%) in 35 patients with the combination of IFN-
a, IL-2 and 5-fluorouracil (5-FU) (Atzpodien et al, 1993a). Given
these promising results, we performed a multicentre confirmatory
study with the same schedule in patients with metastatic renal cell
carcinoma.
PATIENTS AND METHODS
Patients
The study was performed by the Dutch Immunotherapy Working
Party and accrual took place between 1994 and 1996. All patients
had histologically proven renal cell carcinoma, had undergone a
nephrectomy for renal cell carcinoma and documented progression
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the trial applied: bidimensionally measurable disease, WHO
performance status 0–1, age 18–75 years, serum values of creati-
nine ≤ 150 mM, bilirubin ≤ 25 mM, white cell count ³ 4 ´ 109 l–1 and
platelets ³ 100 ´ 109 l–1. Previous hormonal treatment was allowed
provided that the treatment was stopped for at least 
2 weeks. Patients with unstable angina pectoris, recent myocardial
infarction (in the last 6 months) or arrhythmia’s requiring therapy,
active infections, a history of second malignancy with the excep-
tion of adequately treated carcinoma in situ of the cervix or basal
cell carcinoma of the skin, concurrent treatment with immunosup-
pressive agents, bone metastases as only metastatic site, clinical
signs of central nervous system involvement, previous immuno- or
chemotherapy and pregnant or lactating women were excluded.
Written informed consent was obtained from all patients. Before
initiation of this trial, institutional review board approval was
obtained at each of the participating centres.
Study design
The study was an open label phase II study. Patients were treated
as outpatients with an 8-week treatment cycle. Recombinant
human IL-2 (Chiron) 20 MU m–2 was administered subcuta-
neously (s.c.) 3 times a week (t.i.w.) in weeks 1 and 4, and 5 MU
m–2 t.i.w. in weeks 2 and 3. Recombinant human IFN-a 2a (Roche)
6 MU m–2 was administered s.c. once in weeks 1 and 4 as well as
t.i.w. in weeks 2 and 3, and 9 MU m–2 t.i.w. in weeks 5–8. 5-FU
(750 mg m–2) was given as a bolus injection intravenous (i.v.) once
a week in weeks 5–8. Before and after IFN-a or IL-2 administra-
tion, patients received acetaminophen 1000 mg orally. The addi-
tion of naproxen 250 mg for constitutional symptoms caused by
IFN-a and/or IL-2 was allowed. Patients were evaluated weekly
for toxicity. After one 8-week treatment cycle patients were evalu-
ated for response. CTC criteria for toxicity and WHO criteria for
response were used. The treatment cycle was repeated once in case
of response. In case of stable disease the treatment cycle was only
repeated in case of acceptable toxicity and signs of minor
response. In case of grade 3 or 4 toxicity (constitutional symp-
toms) the dose of IFN-a and IL-2 was reduced to 50%. The IL-2
was withdrawn in case of a serum creatinine or bilirubin that failed
to return to grade I toxicity or better, or in case of myocardial
ischaemia. Criteria for removal from the study were tumour
progression whilst on therapy, unacceptable toxicity or inter-
current illness, preventing further treatment or patient refusal.
RESULTS
Six centres included 52 patients. Patients’ characteristics are listed
in Table 1. All patients had undergone a nephrectomy and had
progressive metastatic renal cell carcinoma. The median age was
57 years (range 27–72). The median WHO-performance status
was 1 (0–1), the median number of metastatic sites was 2 (1–5)
and the median time between the diagnosis and the start of treat-
ment was 12.9 months (1–153). Two patients were included
although they had a WHO PS of 2 (Karnofsky score of 70%). Nine
patients received radiotherapy and three patients underwent a
metastasectomy in the period prior to entry of the study. When the
patients were separated in prognostic subgroups according to the
model of Jones, approximately half of the patients belonged to the
good prognostic group (Jones et al, 1993).
Response and survival
In five patients treatment was stopped within 3 weeks after
starting. One patients with rapidly progressive symptomatic bone
metastasis in the second week of treatment was offered radio-
therapy and systemic treatment was discontinued. In one patient
in-growth of a metastasis of the pancreas in the duodenum resulted
in a duodenal bleeding after 2 weeks of treatment; treatment was
stopped and radiotherapy was given. Two patients showed signifi-
cant early progression of their disease within 3 weeks and treat-
ment was stopped. One patient refused further treatment after 2
weeks; he had no grade III or IV toxicity, but suffered from
headaches and nausea grade II.
The patients with early progression (n = 4) are included in the
response analysis. Thus, 51 patients were evaluable for response.
After one treatment cycle, five patients (9.8%) had a partial
response and there were no complete responses; 31 patients
(60.8%) had stable disease and 15 (29.4%) had progressive
disease.
Sixteen patients received a second cycle: four of the five
patients with a partial response and 12 of the 31 patients with
stable disease, but with minor signs of response. One of the five
patients with a partial response did not receive the second cycle
due to toxicity. After the second cycle, one patient with initially a
stable disease reached a partial response. Thus, the overall
response rate was 11.8% (95% CI 2.9–20.7%) in the 51 evaluable
patients and 12.8% (95% CI 3.2–22.4%) in the 47 fully evaluable
patients. Responses occurred most frequently in lung, but also in
lymph nodes and adrenal metastases. Median response duration
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Table 1 Patients’ characteristics
Characteristics No. of patients
Total number of patients (men/women) 52 (39/13)
Median age, years (range) 57 (27–72)
WHO-performance status
03 0
12 0
22
No. of metastatic sites
12 0
21 9
31 1
41
51
Metastatic sites
Lymph nodes 22
Lung 42
Adrenal 3
Liver 9
Bone 6
Renal 7
Pleura 4
Retroperitoneal lesion 4
Other 3
Time between diagnosis and treatment for metastases
≤ 24 months 35
> 24 months 17
Median (range) 12.9 (1–153)
Prognostic subgroupa
Good 25 (48%)
Intermediate 17 (33%)
Poor 10 (19%)
aDivision in prognostic subgroups according to Jones et al (1993).was 8.3 months (3.8–22.4+ months). Median survival was 16.5
months (1.8–30.5+ months) (Figure 1).
Toxicity of treatment
Fifty-two patients were evaluable for toxicity. Grade 3/4 toxicity
occurred in 29/52 (55.8%) of the patients in cycle 1 and in 6/16
(37.5%) of the patients in cycle 2. It consisted mainly of anorexia,
fatigue, nausea, fever and leucocytopenia (Table 2).
Of the 47 fully evaluable patients, only 30 (63.8%) received a
complete first cycle without reduction or delay of treatment. Nine
patients (19.2%) completed the first cycle with a dose reduction or
delay. Eight patients (17%) did not complete the first cycle. Of the
16 patients treated with a second cycle, 13 (81%) received a
complete cycle without reduction or delay of treatment. Two
patients (13%) completed the second cycle with a dose reduction
or delay. Only one patient (6%) did not complete the second cycle.
DISCUSSION
Since the 1980s a large number of studies have been performed
treating patients with metastatic renal cell carcinoma with IFN-a
and/or IL-2. In phase II studies these drugs are associated both as
single agent and in combination, with a response rate between 6
and 25% and a median survival of 8–14 months (Umeda and
Niijima, 1986; Creagan et al, 1991; Gore et al, 1994; Fyfe et al,
1996). In a randomized phase III study the response rates of
patients treated with IL-2, IFN-a or the combination were 6.5%,
7.5% and 18.6% respectively. However, the overall survival rates
in the three groups were not significantly different from one
another, and the median survival times were 12, 13 and 17 months
respectively (Negrier et al, 1998). The rationale for combining
IFN-a and IL-2 is that in vitro IFN-a enhances the cell membrane
expression of major histocompatibility complex (MHC) antigens
to which IL-2-activated T-cells can respond (Guadagni et al,
1989).
To improve these moderate results, several groups have
proposed combination of these cytokines with chemotherapy. 
The mechanisms underlying the supposed synergistic interaction
between immunotherapy and chemotherapy are still speculative.
Arguments for the enhancement of the anti-tumour activity of
immunotherapy by chemotherapy as well as vice versa have been
postulated. When 5-FU is used as monotherapy in patients with
metastatic renal cell carcinoma, the tumour activity is weak, with a
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Table 2 Grade 3/4 toxicity in 52 evaluable patients in cycle 1 and in 16 patients in cycle 2
Toxicity Grade 3 Grade 4 Total no. of patients (%)
Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2
Anorexia 12 3 0 0 12 (23) 3 (19)
Leucocytopenia 9 3 2 0 11 (21) 3 (19)
Malaise 8 2 1 1 9 (17) 3 (19)
Nausea/vomiting 7 2 1 0 8 (15) 2 (13)
Flu-like symptoms 4 1 0 0 4 (8) 1 (6)
Hypotension 4 0 0 0 4 (8) 0
Hypertension 1 1 0 0 1 (2) 1 (6)
Diarrhoea 1 0 0 0 1 (2) 0
Respiratory distress 1 0 0 1 1 (2) 1 (6)
Hyperbilirubinaemia 0 1 1 0 1 (2) 1 (6)
Cutaneous 1 0 0 0 1 (2) 0
Toxicity according to CTC criteria: 1, mild; 2, moderate; 3, severe; 4, life-threatening. Numbers are patients.
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Figure 1 (A) Survival from time of start of treatment. (B) Time to progression from time of start of treatment.response rate less than 10% (Kish et al, 1994). However, it has
been observed that the tumour cells of renal cancer acquire an
increased susceptibility to lymphocyte activated killer (LAK) cells
after incubation with 5-FU (Reiter et al, 1992; Tomita et al, 1993).
Also, a modification in the metabolism of 5-FU by IFN-a has been
reported (Pfeffer and Tamm, 1984; Seymour et al, 1994).
In 1993, Atzpodien et al used a sequential combination of IFN-
a s.c., IL-2 s.c. and 5-FU i.v. and observed an objective response
rate of 48% in 35 patients, with 11% complete responses
(Atzpodien et al, 1993b). Disappointingly, in our study, in which
we treated the patients with the same schedule, the response rate
was only 11.8% with no complete responses. Three other groups
also have used the same schedule as Atzpodien et al and found a
response rate of 38, 16 and 19%, with 9, 0 and 0% complete
responses respectively (Hofmockel et al, 1996; Joffe et al, 1996;
Dutcher et al, 1996). The group of Atzpodien et al has extended
their experience with this schedule and reported response rates of
39% in 120 patients, 39% in 41 patients and 33% in 246 patients
(Lopez Hanninen et al, 1996; Atzpodien et al, 1997; Kirchner et al,
1998). The combination of IFN-a, IL-2 and 5-FU is also used in
other schedules. The most important differences are that either IL-
2 was given as a continuous i.v. infusion and/or the drugs were
administered all three concomitantly. The response rates were 39,
31, 8, 20, 2 and 35% respectively for the reports by Sella et al
(1994), Ellerhorst et al (1997), Negrier et al (1997), Tourani et al
(1998), Ravaud et al (1998) and Ventriglia et al, (1998) (Table 3).
The discrepancy in results between our study and some of the
other studies using the same schedule might be explained by three
factors. First, patient selection based on known and unknown
factors can be an important cause. Half of our patients belonged to
the good prognostic subgroup according to the criteria of Jones et
al (1993). Five of the six responders belonged to that group and the
other to the intermediate prognostic subgroup. There was no
response in the poor prognostic subgroup. It is difficult to compare
our group of patients with that of Atzpodien et al, due to the use of
a different prognostic system (Atzpodien et al, 1993b). When
compared with others, our group showed more favourable prog-
nostic factors than the patients reported by Joffe, but was similar to
the group reported by Tourani (Joffe et al, 1996; Tourani et al,
1998).
A second factor that may have influenced the results is that,
after nephrectomy, we waited until evidence of progression of
disease was established before starting treatment. The spontaneous
regression rate can be as high as 7% (Gleave et al, 1998). It is not
clear if in other studies patients were also included immediately
after nephrectomy.
The third reason can be the high rate of grade 3 or 4 toxicity
(55.8% of the patients in the first cycle). As a consequence only
63% of the patients got the first cycle without delay or dose reduc-
tion. The grade 3 and 4 toxicity was much higher than reported in
most of the other studies (9–18%) using exactly the same schedule
(Hofmockel et al, 1996; Lopez Hanninen et al, 1996) but was
comparable with the toxicity (44%) found by Joffe et al (1996).
In conclusion, we cannot confirm the high response rate in
patients with metastatic renal cell carcinoma treated with the
combination of IFN-a, IL-2 and 5-FU, described by Atzpodien et
al (1993a). To eliminate the influence of unknown differences in
the various populations a phase III study is warranted to determine
the true efficacy of this schedule.
REFERENCES
Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M and Poliwoda H
(1993a) Interleukin-2 in combination with interferon-alpha and 5-fluorouracil
for metastatic renal cell cancer. Eur J Cancer 29A: S6–8
Atzpodien J, Kirchner H, Hanninen EL, Korfer A, Fenner M, Menzel T, Deckert M,
Franzke A, Jonas U and Poliwoda H (1993b) European studies of interleukin-2
in metastatic renal cell carcinoma. Semin Oncol 20: 22–26
Atzpodien J, Lopez Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M,
Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, Scholz H, Wilhelm S,
Pielmeier T, Zakrzewski G, Blum G, Beier J, Müller G, Duensing S, Allhoff E,
Jonas U and Poliwoda H (1995) Multiinstitutional home-therapy trial of
recombinant human interleukin-2 and interferon a-2 in progressive metastatic
renal cell carcinoma. J Clin Oncol 13: 497–501
Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S and
Ganser A (1997) Results of a randomized clinical trial comparing s.c.
interleukin-2, s.c. a-2a-interferon, and i.v. bolus 5-fluorouracil against oral
tamoxifen in progressive metastatic renal cell carcinoma patients. ASCO Proc
16: 326a
Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker
TR, Geeraerts LH, Veeder MH, Gesme DH, Jr and Homburger H (1991) A
randomized prospective assessment of recombinant leukocyte A human
interferon with or without aspirin in advanced renal adenocarcinoma. J Clin
Oncol 9: 2104–2109
Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T and
Atkins M (1996) 5-FU and subcutaneous IL-2 plus s.c. intron in metastatic
renal cell cancer (RCC) patients. ASCO Proc 15: 272
Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M and
Logothetis CJ (1997) Phase II trial of 5-fluorouracil, interferon-a and
continuous infusion interleukin-2 for patients with metastatic renal cell
carcinoma. Cancer 80: 2128–2132
Facendola G, Locatelli MC, Pizzocaro G, Piva L, Pegoraro C, Pallavicini EB,
Signaroldi A, Meregalli M, Lombardi F, Beretta GD, Scanzi R, Labianca R and
Luporini G (1995) Subcutaneous administration of interleukin 2 and interferon-
a-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer 72:
1531–1535
Fossa SD, Kramar A and Droz JP (1994) Prognostic factors and survival in patients
with metastatic renal cell carcinoma treated with chemotherapy or interferon-a.
Eur J Cancer 30A: 1310–1314
Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC (1996)
Long-term response data for 255 patients with metastatic renal cell carcinoma
treated with high-dose recombinant interleukin-2 therapy [letter]. J Clin Oncol
14: 2410–2411
Gleave M, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Moore M, Paton
V, Bajamonde A and the Canadian Urologic Oncology Group (1998) Interferon
g-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med
338: 1265–1271
Immunochemotherapy in renal cell carcinoma 775
British Journal of Cancer (2000) 82(4), 772–776 © 2000 Cancer Research Campaign
Table 3 Phase II studies in MRCC with the combination IL-2, IFN-a, and 
5-FU
Author Response rate (%) Country
Atzpodien, 1993b 48 Germany
Hofmockel, 1996 38 Germany
Joffe, 1996 16 UK
Dutcher, 1996 19 USA
Lopez-Hanninen, 1996 39 Germany
Atzpodien, 1997 39 Germany
Kirchner, 1998 33 Germany
van Herpen, 1999 12 The Netherlands
Sella, 1994 39 USA
Ellerhorst, 1997 31 USA
Negrier, 1997 8 France
Tourani, 1998 20 France
Ravaud, 1998 2 France
Ventriglia, 1998 35 Argentina
Above the double line the studies that used exactly the same schedule as
Atzpodien are summarized. Below that line the studies with another schedule
are enumerated.776 CML van Herpen et al
British Journal of Cancer (2000) 82(4), 772–776 © 2000 Cancer Research Campaign
Gore ME, Galligioni E, Keen CW, Sorio R, Loriaux EM, Grobben HC and Franks
CR (1994) The treatment of metastatic renal cell carcinoma by continuous
intravenous infusion of recombinant interleukin-2. Eur J Cancer 30A:
329–333
Guadagni F, Schlom J, Johnston WW, Szpak CA, Goldstein D, Smalley R, Simpson
JF, Borden EC, Pestka S and Greiner JW (1989) Selective interferon-induced
enhancement of tumor-associated antigens on a spectrum of freshly isolated
human adenocarcinoma cells. J Natl Cancer Inst 81: 502–512
Hofmockel G, Langer W, Theiss M, Gruss A and Frohmuller HG (1996)
Immunochemotherapy for metastatic renal cell carcinoma using a regimen of
interleukin-2, interferon-a and 5-fluorouracil. J Urol 156: 18–21
Jayson GC, Middleton M, Lee SM, Ashcroft L and Thatcher N (1998) A randomized
phase II trial of interleukin 2 and interleukin 2-interferon a in advanced renal
cancer. Br J Cancer 78: 366–369
Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova
G, Adams J, Crossley A, Johnson PW, Whicher JT and Selby PJ (1996) A
phase II study of interferon-a, interleukin-2 and 5-fluorouracil in advanced
renal carcinoma: clinical data and laboratory evidence of protease activation.
Br J Urol 77: 638–649
Jones M, Philip T, Palmer P, Von der Maase H, Vinke J, Elson P, Franks CR and
Selby . (1993) The impact of interleukin-2 on survival in renal cancer: a
multivariate analysis. Cancer Biother 8: 275–288
Kirchner H, Buer J, Probst-Kepper M, Franzke A, Hoffmann R, Wittke F, Ganser A
and Atzpodien J (1998) Risk and long-term outcome in metastatic renal cell
carcinoma patients receiving s.c. interleukin-2, s.c. interferon-a2a and i.v. 5-
fluorouracil. ASCO Proc 17: 310a
Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR and Flanigan
RC (1994) Evaluation of low dose continuous infusion 5-fluorouracil in
patients with advanced and recurrent renal cell carcinoma. A Southwest
Oncology Group Study. Cancer 74: 916–919
Kjaer M (1988) The role of medroxyprogesterone acetate (MPA) in the treatment of
renal adenocarcinoma. Cancer Treat Rev 15: 195–209
Lopez Hanninen E, Kirchner H and Atzpodien J (1996) Interleukin-2 based home
therapy of metastatic renal cell carcinoma: risks and benefits in 215
consecutive single institution patients. J Urol 155: 19–25
Linehan MW, Shipley WU and Parkinson DR (1997) Cancer of the kidney and
ureter. In: Cancer. Principles and Practice of Oncology, De Vita VT Jr, Hellman
S and Rosenberg SA (eds), pp. 1271–1299. Lippincott-Raven: Philadelphia.
Negrier S, Escudier B, Douillard JY, Lesimple T, Rossi JF, Viens P, DiStefano-
Louineau D, Drevon M, Gomez F, Caty A and The French Immunotherapy
Group (1997) Randomized study of interleukin-2 (IL2) and interferon (IFN)
with or without 5-FU (FUCY study) in metastatic renal cell carcinoma
(MRCC). ASCO Proc 16: 326a
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A,
Mercatello A, Peny J, Mousssseau M, Philip T and Tursz T (1998)
Recombinant human interleukin-2, recombinant human interferon-a-2a, or
both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–1278
Palmer PA, Atzpodien J, Philip T, Negrier S, Kirchner H, Von der Maase H,
Geertsen P, Evers P, Loriaux E, Oskam R, Roest G, Vinke J and Franks C
(1993) A comparison of 2 modes of administration of recombinant interleukin-
2: continuous intravenous infusion alone versus subcutaneous administration
plus interferon a in patients with advanced renal cell carcinoma. Cancer
Biother 8: 123–136
Pfeffer LM, Tamm I (1984) Interferon inhibition of thymidine incorporation into DNA
through effects on thymidine transport and uptake. J Cell Physiol 121: 431–436
Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY,
Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M and Negrier S (1998)
Subcutaneous interleukin-2, interferon a-2a, and continuous infusion of
fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial.
Groupe Francais d’Immunotherapie. J Clin Oncol 16: 2728–2732
Reiter Z, Ozes ON, Blatt LM and Taylor MW (1992) A dual anti-tumor effect of a
combination of interferon-a or interleukin-2 and 5-fluorouracil on natural killer
(NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 62: 103–111
Sella A, Zukiwski AA, Robinson E, Kilbourn R, Ellerhorst J, Amato R and Logothetis
C (1994) Interleukin-2 (IL-2) with Interferon-a (IFN-a) and 5-Fluorouracil (5-
FU) in patients with metastatic renal cell cancer. ASCO Proc 13: 237
Seymour MT, Patel N, Johnston A, Joel SP and Slevin ML (1994) Lack of effect of
interferon a 2a upon fluorouracil pharmacokinetics. Br J Cancer 70: 724–728
Tomita Y, Imai T, Katagiri A, Kimura M, Saitoh K and Sato S (1993) 5-Fluorouracil
increases susceptibility of renal cell cancer cell lines to lymphokine-activated
killer cells: evidence for alteration not at the level of recognition but at a post-
binding stage of the lytic cycle. Cancer Lett 75: 27–34
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B,
Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E,
Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D,
Lucas V, Krakowski I, Larregain Fournier D, Abourachid H, Andrieu JM and
Chastang C (1998) Outpatient treatment with subcutaneous interleukin-2 and
interferon a administration in combination with fluorouracil in patients with
metastatic renal cell carcinoma: results of a sequential non-randomized phase II
study. Subcutaneous Administration Proleukin Program Cooperative Group. 
J Clin Oncol 16: 2505–2513
Umeda T, Niijima T (1986) Phase II study of interferon a on renal cell carcinoma.
Summary of three collaborative trials. Cancer 58: 1231–1235
Ventriglia M, Estevez R and Tiscomia A (1998) Chemoimmunotherapy with
interleukin-2, interferon-a-2b and 5-fluorouracil in outpatients with advanced
renal cell carcinoma. ASCO Proc 17: 347a